Search

Introduction:Cervical carcinoma is the second most common malignancy in women worldwide. It is estimated that over a million women worldwide currently have cervical cancer. Worldwide, cervical cancer is both the fourth-most common cancer and the fourth-most common cause of death from cancer in women. In 2012, 528, 000 new cases of cervical cancer were diagnosed, and 266, 000 women died of the disease (GLOBOCAN 2012), nearly 90% of them in lowto middle-income class countries. Multifactorial causation, potential for prevention, and the sheer threat it poses make cervical cancer an important disease for in-depth studies, as has been attempted by this paper by studying the hypoxic marker. Recently, there has been increasing interest in the identification of biomarkers able to predict both response to treatment and survival. Aim: The aim of this study was to evaluate the association of hypoxic marker Carbonic anhydrase (CAIX) markers to predict the clinical outcome of patients with cervical carcinoma. Materials and methods:This study was conducted on biopsy proven previously untreated cases of cancer cervix who presented to the Department of Radiotherapy at King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India. The study was a single institution, non-randomised, prospective study to evaluate carbonic anhydrase IX as a biomarker in cancer cervix patients undergoing radiotherapy. Sample size: Total 75 samples • 25 healthy control subjects (Age and sex matched) • 25 cancer cervix patients (duplicate samples i.e. baseline and follow up). Approximately 2 ml of blood was withdrawn before initiation of treatment and at the time of first follow up. Standard treatment was given as external beam radiotherapy (EBRT) with concurrent chemotherapy followed by intracavitary radiotherapy (ICRT). Blood samples was analysed for the level of CAIX..Statistical analyses was performed with the SPSS software package v13.0. Results: Pre-treatment high level of carbonic anhydrase IX correlated with poor treatment outcome. [ABSTRACT FROM AUTHOR]

Study of Copper, Zinc and Selenium associated with Superoxide Dismutase, Catalase and Glutathione Peroxidase level in serum of Breast cancer patients of North India A. K. Singh, V. Jain, G. N. Singh 1Department of Surgery, King George's Medical University, 2Surgery, King Georg's Medical University, Lucknow, India I declare that my presentation : will not include discussion of unapproved or "off-label" usage of a commercial product or device. Introduction: Breast cancer in women is most common cancer world wide and second most common cancer overall. Trace elements and antioxidant enzymes have been found involved in development and prevention of malignancies including breast cancer. This study aims to find out association between trace elements: copper, zinc and selenium along with antioxidant enzymes: SOD, Catalase, Glutathione peroxidise levels in breast cancer patients of various clinical stages. Materials & Methods: This Prospective observational cohort study is conducted in department of general surgery, King George's Medical University, Lucknow, U.P., India. Blood sample of 152 breast cancer patients were analysed and age matched with 152 controls. Unpaired t-test is used to compare the antioxidant enzymesand trace elements between cases and controls. The plasma level of copper, zinc, selenium and antioxidant enzymes (SOD, Catalase, Glutathione peroxidase) were analysed in both groups to find out any statistically significant correlation. Results: Plasma copper levels (μgm/dl) are higher in cases with mean of 132.43±6.10 vs controls 113.58±11.70 with p<0.0001. Plasma zinc levels (μgm/dl) (case: 88.25±6.30, control: 109.92±8.33, p<0.0001)) and selenium (μmol/dl) (case:3.27±0.18, control: 3.33±0.22 (p<0.0001)) are lower in breast cancer patients. Mean levels of Superoxide dismutase (IU/ ml) (case: 9.49±6.25, control: 27.04±4.39, p<0.0001), Catalase (IU/ ml) (case:0.09±0.08, control: 0.29±0.24, p<0.0001) and Glutathione peroxidise (nanomolNADPH oxidase/min/mg protein) (case: 16.96±10.20, control; 46.70±14.18, p<0.0001) are observed to be lower in breast cancer patients. Blood level of selenium, Superoxide dismutase, Catalase and Glutathione peroxidase are found to have a direct correlation while Plasma levels of Copper has inverse correlation with advanced stages of breast cancer Conclusion: Lower levels of antioxidant enzymes (Superoxide dismutase, Catalase and Glutathione peroxidase) and selenium found in breast cancer patients along with higher copper levels suggest that these metals and antioxidant enzymes play role in etiopathogenesis and aggressiveness of disease. This gives insight to initiate research for additive therapy of antioxidants and selenium in patients of breast cancer to achieve better outcome. Disclosure of Interest: None Declared. [ABSTRACT FROM AUTHOR]